GASTROINTESTINAL ABSORPTION OF PRAVASTATIN IN HEALTHY-SUBJECTS

被引：33

作者：

TRISCARI, J ^{[1
]}

ODONNELL, D ^{[1
]}

ZINNY, M ^{[1
]}

PAN, HY ^{[1
]}

机构：

[1] MED & TECH RES ASSOC INC, BOSTON, MA USA

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 1995年 / 35卷 / 02期

关键词：

D O I：

10.1002/j.1552-4604.1995.tb05002.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The bioavailability of pravastatin, a hypocholesterolmic agent, may be enhanced by decreasing its exposure to stomach contents, where it may be converted nonenzymatically to a relatively inactive metabolite. The pharmacokinetics of pravastatin and its metabolite were determined after infusion of pravastatin directly into the stomach (locus for greatest bioavailability for the metabolite), duodenum (greastest bioavailability for pravastatin), jejunum, or ileum. An enterically coated formulation of pravastatin may increase its bioavailability.

引用

收藏

页码：142 / 144

页数：3

相关论文

共 12 条

[1] LIPID EMULSIONS AS DRUG DELIVERY SYSTEMS [J].

DAVIS, SS ;

WASHINGTON, C ;

WEST, P ;

ILLUM, L ;

LIVERSIDGE, G ;

STERNSON, L ;

KIRSH, R .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 507 :75-88

[2]

EVERETT DW, 1991, DRUG METAB DISPOS, V19, P740

[3] DETERMINATION OF PRAVASTATIN SODIUM AND ITS MAJOR METABOLITES IN HUMAN-SERUM PLASMA BY CAPILLARY GAS-CHROMATOGRAPHY NEGATIVE-ION CHEMICAL IONIZATION MASS-SPECTROMETRY [J].

FUNKE, PT ;

IVASHKIV, E ;

ARNOLD, ME ;

COHEN, AI .

BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, 1989, 18 (10) :904-909

[4] SINGLE-DOSE PHARMACOKINETICS OF PRAVASTATIN AND METABOLITES IN PATIENTS WITH RENAL IMPAIRMENT [J].

HALSTENSON, CE ;

TRISCARI, J ;

DEVAULT, A ;

SHAPIRO, B ;

KEANE, W ;

PAN, H .

JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 32 (02) :124-132

[5] CLINICAL IMPLICATIONS OF NEW DRUGS FOR LOWERING PLASMA-CHOLESTEROL CONCENTRATIONS [J].

ILLINGWORTH, DR .

DRUGS, 1991, 41 (02) :151-160

[6]

JULIANO RL, 1987, ANN NY ACAD SCI, P507

[7]

NEWMAN TJ, 1990, J DRUG DEV, V275, P281

[8] PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND THE HMG-COA REDUCTASE INHIBITORS PRAVASTATIN AND LOVASTATIN [J].

PAN, HY ;

TRISCARI, J ;

DEVAULT, AR ;

SMITH, SA ;

WANGIVERSON, D ;

SWANSON, BN ;

WILLARD, DA .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (06) :665-670

[9] CLINICAL-PHARMACOLOGY OF PRAVASTATIN, A SELECTIVE INHIBITOR OF HMG-COA REDUCTASE [J].

PAN, HY .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 :S15-S18

[10] PHARMACOKINETICS AND PHARMACODYNAMICS OF PRAVASTATIN ALONE AND WITH CHOLESTYRAMINE IN HYPERCHOLESTEROLEMIA [J].

PAN, HY ;

DEVAULT, AR ;

SWITES, BJ ;

WHIGAN, D ;

IVASHKIV, E ;

WILLARD, DA ;

BRESCIA, D .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (02) :201-207